September 2026 Research Update

This month added a clearer picture that complement-blocking drugs can show very different patterns depending on the situation. In people treated for aHUS, ravulizumab was linked with continued remission and lab evidence that the drug was blocking the terminal complement pathway. In contrast, among people who later had a major heart attack (STEMI), being on a C5 inhibitor beforehand was linked with higher risks of several serious complications in the following months. [1] [2]

In a small aHUS group (6 people), blood samples taken while on ravulizumab showed normal levels of a lab readout of terminal complement attack on endothelial cells (cells lining blood vessels), and everyone remained in or reached clinical remission. This supports the idea that, at least in this setting, ravulizumab was doing what it is designed to do biologically. Because the study was very small and did not compare against another treatment, it mainly adds reassurance about target blocking rather than proving long-term outcomes. [1]

A separate global database study looked at adults who had a STEMI and compared those with prior C5 inhibitor exposure (eculizumab or ravulizumab) to matched patients without C5 inhibitors. At 365 days, the C5 inhibitor group had higher risks of death, stroke/TIA, blood clots, major cardiovascular events, and acute kidney injury; at 30 days, blood clots, major cardiovascular events, and acute kidney injury were higher but death was not significantly different. Arrhythmias were less common in the C5 inhibitor group. This result does not show that the drugs caused harm, but it does show that C5 blockade did not look cardioprotective in this real-world STEMI setting, and that outcomes after STEMI may be more complicated for people who have needed these medicines. [2]

For patients and caregivers, these studies mainly help separate two questions: whether complement blockers can control aHUS biology, and whether they protect against complications in other emergencies like heart attacks. The small aHUS report supports that ravulizumab can fully block the terminal complement signal in blood tests while people are in remission, which may matter for future research on monitoring. The heart attack study may matter now for understanding risk discussions after STEMI, but it cannot prove the drug is the reason for worse outcomes because people on C5 inhibitors may differ in important ways that the study could not fully measure. [1] [2]

This month, studies focused on practical, higher-risk situations where aHUS care often becomes urgent: childhood anti-factor H antibody aHUS and kidney transplantation in people with complement dysregulation. Across these settings, a consistent message was that underlying complement-related abnormalities mattered for who relapsed or had recurrence after transplant. The reports also described that plasma exchange and immune-targeting medicines were commonly used and were linked with control of disease activity in the short term. [3] [4]

In 40 children with anti-factor H antibody-associated aHUS treated with abbreviated plasma exchange plus immunosuppression, about half had complete kidney recovery at a median follow-up of 24 months, while the other half had chronic kidney disease stages 2 to 4. Relapses happened, often within 6 months, and time on dialysis was the only factor that independently predicted kidney recovery. This helps put numbers around the range of longer-term kidney outcomes even when remission is achieved. [3]

In a kidney transplant cohort of 38 recipients with complement dysregulation, post-transplant thrombotic microangiopathy recurred in 7 people (18.4%), and all recurrences were in those with complement gene abnormalities. People with isolated anti-factor H antibodies did not have recurrence in this report. Disease-directed therapy (plasma exchange and rituximab, with a rescue dose of eculizumab in one patient) was reported to control recurrences with graft preservation, although serious infections and one fungal-related graft loss were also described in the context of heavy immunosuppression. [4]

For families dealing with childhood aHUS or transplant decisions, these studies add clearer expectations about where relapses or recurrence may cluster and what outcomes can look like over 1 to 2 years. They reinforce that identifying complement gene changes or anti-factor H antibodies can be important for understanding risk, even though the studies do not test a single best approach. The evidence here comes from single-center, retrospective care experiences, so it is most useful for setting realistic questions to ask and for guiding future research rather than giving a one-size-fits-all plan. [3] [4]

This month included a major pediatric guidance document that tries to standardize how children with aHUS and related conditions are evaluated and managed worldwide. The document compiles expert-agreed recommendations and practice points across several real-life scenarios, including genetic aHUS, autoimmune (anti-factor H antibody) aHUS, transplant-related issues, and secondary thrombotic microangiopathy. Its main contribution is bringing many areas of practice under one shared framework, including settings where access to testing and medicines differs. [5]

The paper reported 51 clinical practice recommendations and 9 practice points developed through literature review and expert consensus with high agreement. It explicitly addresses how to approach diagnosis and management decisions across different health systems. Because it is a recommendations paper, it does not provide new patient outcome results, but it summarizes what the group viewed as best-supported practices at the time. [5]

For patients and caregivers, this document may matter now as a reference that describes what many pediatric experts consider important to check and consider in aHUS and related thrombotic microangiopathy conditions. Its value is mostly in creating shared language and expectations about workups and care pathways rather than changing what is known about outcomes. It also highlights that care can look different depending on local resources, which may help families understand why testing or treatment options vary across regions. [5]